RecruitingPhase 2NCT04765137

Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)

Targeting Cerebrovascular Reactivity for Precision Medicine: Pilot Trial of Atorvastatin

Sponsor

Johns Hopkins University

Enrollment

20 participants

Start Date

May 21, 2021

Study Type

INTERVENTIONAL

Conditions

Mild Cognitive Impairment

Summary

The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.

Eligibility

Min Age: 60 YearsMax Age: 95 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Atorvastatin Oral Tablet for people with mild cognitive impairment. The study is currently recruiting participants at 1 location. People eligible for this study include aged 60 Years to 95 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAtorvastatin Oral Tablet

Atorvastatin pill 40 mg to be taken every night

Locations(1)

Johns Hopkins University, Bayview Medical Center

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04765137

Related Trials

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

NCT071696301 location

Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.

NCT075123621 location